Bleeding Disorder Treatment Market Size is expected to grow considerably from 2022 to 2028. This is on account of the rising awareness about the role of recombinant DNA technology in producing effective and safe therapeutic medications, which can reduce the potential transmission of blood-borne diseases. In addition, the high incidence of bleeding disorders in females living with platelet disorders and other rare factor deficiencies in the U.S. will also contribute to overall industry dynamics in the years ahead. Bleeding disorders refer to a group of conditions that affects the body’s blood clotting process. These disorders, including acquired platelet function defects, may lead to prolonged and heavy bleeding after an injury and are developed due to several factors like severe liver disease or vitamin K deficiency.
Rising burden of hemophilia is among the prominent factors amplifying the bleeding disorder treatment market outlook through 2022-2028. The estimated prevalence of this type of congenital bleeding disorder is 12 cases per 100,000 males for hemophilia A and 3.7 cases per 100,000 males for hemophilia B in the U.S., according to the CDC’s data. Furthermore, the increasing burden of anemia and severe liver diseases will also augment the market share over the estimated timeline, as these diseases may lead to blood coagulation issues in patients.
Considering type, the bleeding disorder treatment market from the Von Willebrand disease segment will register commendable revenue by 2028. This is owing to the significant advancement of replacement therapy to treat this highly prevalent, inherited bleeding disorder. Based on drug class, the fibrin sealants segment is anticipated to hold a considerable share in the upcoming years. The segmental expansion is driven by the increased risks of postoperative bleeding among patients with blood clotting disorders, and the strong awareness about the effectiveness of this drug type in dental work as it promotes clotting and healing.
The Middle East and Africa bleeding disorder treatment market is set to exhibit an appreciable growth rate through 2028, given the rapid reforms and spending in the healthcare sector in Saudi Arabia. In February 2020, Grifols inked an agreement with the PIF (Public Investment Fund), the Saudi sovereign wealth fund, to start the production of blood plasma-based medicines. Such initiatives, along with the mounting incidence of non-alcoholic fatty liver diseases among obese and overweight adults in South Africa, are projected to impel the deployment of platelet disorder treatments over the forecast spell.
Key bleeding disorder treatment market players include Bioverativ (Sanofi), Amgen, Xenetic Biosciences, Bristol-Myers Squibb Company, Alnylam Pharmaceuticals, Bayer AG, Biogen, Novo Nordisk, CSL Behring, Genentech (Roche Holding), Pfizer, Baxter International, Janssen Global Services (Johnson & Johnson), Swedish Orphan Biovitrum AB (Investor AB), and Sanofi S.A., among others. Strategic business expansions and Innovative product launches are the key initiatives being undertaken by these companies to boost their presence in the global market. For instance, in November 2021, Genentech announced the presentation of data from its hematology portfolio at the ASH (American Society of Hematology) Annual Meeting and Exposition, which spans numerous bleeding disorders like hemophilia.
Amid the global push towards developing effective vaccines against the COVID-19 disease, a small risk of autoimmune bleeding disorders following the first vaccine dose was reported. According to the guidance from organizations such as the U.S. National Hemophilia Foundation and the World Federation of Hemophilia, prior to receiving the coronavirus vaccine, patients with moderate or severe hemophilia were recommended to be pre-medicated with clotting factors, such as a factor IX (FIX) and factor VIII (FVIII) injection. These conditions are likely to assert a positive influence on the bleeding disorder treatment industry over the coming years.
Market, by Type
Market, by Drug Class
The above information is provided for the following regions and countries: